Sorafenib prolongs survival in patients with advanced RCC

  • Published 2007 in Nature Clinical Practice Oncology


Systemic therapies for patients with renal cell carcinoma (RCC) include high-dose interleukin 2 and interferon α; however, these cytokines rarely induce complete response or prolonged survival and are not always well tolerated. Sorafenib, a multiprotein kinase inhibitor, has been shown to have antitumor activity in renal adenocarcinoma animal models and to… (More)
DOI: 10.1038/ncponc0751


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.